Skip to main content

CORRECTION article

Front. Immunol., 03 May 2019
Sec. Molecular Innate Immunity
Volume 10 - 2019 | https://doi.org/10.3389/fimmu.2019.00994
This article is part of the Research Topic Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads View all 15 articles

Corrigendum: Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction

This article is a correction to:

  1. Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction

    1. Read original article
\nEbru KarasuEbru Karasu1Bo NilssonBo Nilsson2Jrg Khl,Jörg Köhl3,4John D. LambrisJohn D. Lambris5Markus Huber-Lang*Markus Huber-Lang1*
  • 1Institute for Clinical and Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany
  • 2Department of Immunology, Genetics and Pathology (IGP), Laboratory C5:3, Uppsala University, Uppsala, Sweden
  • 3Institute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany
  • 4Division of Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, United States
  • 5Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, United States

A Corrigendum on
Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction

by Karasu, E., Nilsson, B., Köhl, J., Lambris, J. D., and Huber-Lang, M. (2019). Front. Immunol. 10:543. doi: 10.3389/fimmu.2019.00543

In the original article, we neglected to include a conflict of interest statement of Prof. John D. Lambris.

JL is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogs, such as AMY-101) and is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. JL is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals [i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives].

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: trauma, sepsis, hemorrhagic shock, MODS, complement activation, complement dysregulation, complement therapeutics, clinical trial

Citation: Karasu E, Nilsson B, Köhl J, Lambris JD and Huber-Lang M (2019) Corrigendum: Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. Front. Immunol. 10:994. doi: 10.3389/fimmu.2019.00994

Received: 16 April 2019; Accepted: 17 April 2019;
Published: 03 May 2019.

Approved by:

Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2019 Karasu, Nilsson, Köhl, Lambris and Huber-Lang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Markus Huber-Lang, markus.huber-lang@uniklinik-ulm.de

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.